JP2015145410A5 - - Google Patents

Download PDF

Info

Publication number
JP2015145410A5
JP2015145410A5 JP2015079415A JP2015079415A JP2015145410A5 JP 2015145410 A5 JP2015145410 A5 JP 2015145410A5 JP 2015079415 A JP2015079415 A JP 2015079415A JP 2015079415 A JP2015079415 A JP 2015079415A JP 2015145410 A5 JP2015145410 A5 JP 2015145410A5
Authority
JP
Japan
Prior art keywords
composition according
tablet
composition
substituted
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015079415A
Other languages
English (en)
Other versions
JP6147290B2 (ja
JP2015145410A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015145410A publication Critical patent/JP2015145410A/ja
Publication of JP2015145410A5 publication Critical patent/JP2015145410A5/ja
Application granted granted Critical
Publication of JP6147290B2 publication Critical patent/JP6147290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. (ｉ)副甲状腺ホルモン(PTH)または少なくとも１−28位のアミノ酸を含むそのフラグメント；
    (ii)式I:
    ［式中、
    R1、R2、R3およびR4は、独立して、水素、-OH、-NR6R7、ハロゲン、C1-C4アルキル、またはC1-C4アルコキシであり;
    R5は、置換または非置換C2-C16アルキレン、置換または非置換C2-C16アルケニレン、置換または非置換C1-C12アルキル(アリーレン)、または置換または非置換アリール(C1-C12アルキレン)であり；そして
    R6およびR7は、独立して、水素、酸素、またはC1-C4アルキルである］
    で示される化合物またはその水和物もしくはアルコール溶媒和物である送達剤；
    (iii)崩壊剤；および
    (iv)希釈剤
    を含み、該送達剤は胃腸環境で固体不溶性型から可溶性型に変換され、胃媒体(gastric media)中で20分以下で80%以上の溶解(溶出)時間を有する、錠剤形態の経口医薬組成物。
  2. 2分以下の崩壊時間を有する、請求項１に記載の組成物。
  3. 崩壊剤が超崩壊剤である、請求項１または２に記載の組成物。
  4. 錠剤が3Kpから20Kpの硬度を有する、請求項１〜３のいずれかに記載の組成物。
  5. 錠剤が5Kpから15Kpの硬度を有する、請求項１〜４のいずれかに記載の組成物。
  6. 錠剤が１分未満の崩壊時間および5Kpから7Kpの硬度を有する、請求項４に記載の組成物。
  7. PTHがPTH 1-34である、請求項１〜６のいずれかに記載の組成物。
  8. 送達剤がN-(5-クロロサリチロイル)-8-アミノカプリル酸(5-CNAC)またはその塩である、請求項１〜７のいずれかに記載の組成物。
  9. 送達剤が5-CNACの二ナトリウム塩である、請求項８に記載の組成物。
  10. 希釈剤が微結晶性セルロースである、請求項１〜９のいずれかに記載の組成物。
  11. 錠剤が腸溶性コーティングを含まない、請求項１〜１０のいずれかに記載の組成物。
  12. 錠剤がペプチダーゼ阻害剤を含まない、請求項１１に記載の組成物。
  13. 崩壊剤がクロスポビドンおよび／またはポビドンである、請求項１〜１２のいずれかに記載の組成物。
JP2015079415A 2005-11-17 2015-04-08 医薬組成物 Expired - Fee Related JP6147290B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73763105P 2005-11-17 2005-11-17
US60/737,631 2005-11-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012135063A Division JP6049317B2 (ja) 2005-11-17 2012-06-14 医薬組成物

Publications (3)

Publication Number Publication Date
JP2015145410A JP2015145410A (ja) 2015-08-13
JP2015145410A5 true JP2015145410A5 (ja) 2015-09-24
JP6147290B2 JP6147290B2 (ja) 2017-06-14

Family

ID=37875983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008541365A Withdrawn JP2009515993A (ja) 2005-11-17 2006-11-16 医薬組成物
JP2012135063A Expired - Fee Related JP6049317B2 (ja) 2005-11-17 2012-06-14 医薬組成物
JP2015079415A Expired - Fee Related JP6147290B2 (ja) 2005-11-17 2015-04-08 医薬組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2008541365A Withdrawn JP2009515993A (ja) 2005-11-17 2006-11-16 医薬組成物
JP2012135063A Expired - Fee Related JP6049317B2 (ja) 2005-11-17 2012-06-14 医薬組成物

Country Status (10)

Country Link
US (3) US20080255048A1 (ja)
EP (1) EP1951207A2 (ja)
JP (3) JP2009515993A (ja)
KR (2) KR101432313B1 (ja)
CN (1) CN101309674A (ja)
AU (1) AU2006318815B2 (ja)
BR (1) BRPI0618723A2 (ja)
CA (1) CA2626933C (ja)
RU (1) RU2469709C2 (ja)
WO (1) WO2007061829A2 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007061829A2 (en) * 2005-11-17 2007-05-31 Novartis Ag Pharmaceutical composition
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
CN103619175B (zh) 2011-04-12 2016-08-17 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
JP6356660B2 (ja) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
HRP20231060T1 (hr) 2012-03-22 2023-12-22 Novo Nordisk A/S Pripravci peptida glp-1 i njihova priprava
TR201903918T4 (tr) 2012-03-22 2019-04-22 Novo Nordisk As Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
IL283258B2 (en) * 2015-02-09 2023-11-01 Entera Bio Ltd A preparation for the treatment of hypothyroidism
AU2017311698A1 (en) * 2016-08-17 2019-04-04 Entera Bio Ltd. Formulations for oral administration of active agents
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CN111116684B (zh) * 2019-12-31 2020-09-25 厦门甘宝利生物医药有限公司 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536A (en) 1837-12-26 Beady binder for binding newspapers
US647A (en) 1838-03-21 Improved fishing-seine for deep water
US5866A (en) 1848-10-17 Dentist s deill
US5773A (en) 1848-09-19 Sizing and drying cotton-batting
US608618A (en) 1898-08-09 Thomas millen
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JP2609022B2 (ja) * 1990-11-29 1997-05-14 北陸製薬株式会社 ポリカルボフィルカルシウム含有製剤
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
BR9607189A (pt) * 1995-02-08 1997-11-11 Yamanouchi Europ Bv Formas de dosagem oral contendo um antibiótico de b-lactama
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
IL154537A0 (en) 2000-08-29 2003-09-17 Nobex Corp 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
CZ307145B6 (cs) * 2001-06-01 2018-02-07 Novartis Ag Kompozice pro orální podání, použití této kompozice a souprava pro stimulaci nové kostní tvorby
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
KR20050046776A (ko) * 2002-09-13 2005-05-18 사이덱스 인크 유도체화된 사이클로덱스트린으로 안정화한 수성 충전조성물을 포함하는 캅셀
EP1643978A1 (en) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
CN1856321B (zh) 2003-07-23 2012-10-03 诺瓦提斯公司 降钙素在骨关节炎中的用途
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
WO2007061829A2 (en) * 2005-11-17 2007-05-31 Novartis Ag Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2015145410A5 (ja)
JP2019048894A5 (ja)
JP2013526482A5 (ja)
JP2019511550A5 (ja)
JP2012509348A5 (ja)
JP2017506627A5 (ja)
JP2018518537A5 (ja)
JP2016534063A5 (ja)
JP2014507446A5 (ja)
JP2020097577A5 (ja)
JP2009502793A5 (ja)
JP2016006096A5 (ja)
RU2013119966A (ru) Композиция, улучшающая растворимость плохорастворимого лекарственного препарата
JP2016537347A5 (ja)
JP2009503045A5 (ja)
JP2009515993A5 (ja)
JP2015510916A5 (ja)
JP2010521516A5 (ja)
RU2008123380A (ru) Фармацевтическая композиция
CY1120852T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας
JP2019519533A5 (ja)
JP2017508817A5 (ja)
JP2020523327A5 (ja)
JP2017505809A5 (ja)
EA201290659A1 (ru) Новая композиция ретигабина